Baldwin Wealth Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Baldwin Wealth Partners’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$6.14K	–	808
2023 Q1	$6.14K	Hold	500	–	–	﹤0.01%	662
2022 Q4	$5.73K	Hold	500	–	–	﹤0.01%	649
2022 Q3	$2K	Hold	500	–	–	﹤0.01%	627
2022 Q2	$3K	Hold	500	–	–	﹤0.01%	642
2022 Q1	$3K	Hold	500	–	–	﹤0.01%	637
2021 Q4	$2K	Hold	500	–	–	﹤0.01%	609
2021 Q3	$2K	Hold	500	–	–	﹤0.01%	622
2021 Q2	$3K	Hold	500	–	–	﹤0.01%	621
2021 Q1	$3K	Hold	500	–	–	﹤0.01%	591
2020 Q4	$3K	Hold	500	–	–	﹤0.01%	524
2020 Q3	$2K	Hold	500	–	–	﹤0.01%	515
2020 Q2	$2K	Hold	500	–	–	﹤0.01%	512
2020 Q1	$1K	Hold	500	–	–	﹤0.01%	544
2019 Q4	$2K	Hold	500	–	–	﹤0.01%	528
2019 Q3	$2K	Sell	500 -136	-21%	-$680	﹤0.01%	503
2019 Q2	$3K	Hold	636	–	–	﹤0.01%	491
2019 Q1	$3K	Hold	636	–	–	﹤0.01%	489
2018 Q4	$2K	Hold	636	–	–	﹤0.01%	490
2018 Q3	$3K	Hold	636	–	–	﹤0.01%	501
2018 Q2	$2K	Hold	636	–	–	﹤0.01%	501
2018 Q1	$4K	Buy	+636	New	+$5.26K	﹤0.01%	462

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Baldwin Wealth Partners's MACK Position: Q2 2023 in Review

Baldwin Wealth Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2023, closing a stake of 500 shares — an estimated $6.14K sold.

Baldwin Wealth Partners first reported a position in MACK in Q1 2018 and held it in 21 quarters. The position peaked at $6.14K in Q1 2023. 62 funds tracked by Wall St. Rank hold MACK as of Q2 2023.

Baldwin Wealth Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Baldwin Wealth Partners sold 500 Merrimack Pharmaceuticals, Inc. shares in Q2 2023, an estimated $6.14K.
Baldwin Wealth Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2018 and held it in 21 quarters.
Baldwin Wealth Partners's Merrimack Pharmaceuticals, Inc. position peaked at $6.14K in Q1 2023.
62 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2023.

Based on Baldwin Wealth Partners's 13F filing for Q2 2023, filed 14 Jul 2023.